Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma

Inclusion Criteria

• •Histologically or cytologically confirmed adenocarcinoma arising from the ovary, fallopian tubes, or peritoneum (i.e., peritoneal serous papillary adenocarcinoma)
• •Received prior treatment with either cisplatin or carboplatin in combination with paclitaxel or docetaxel as first-line chemotherapy
• •Radiographic evidence of progressive disease and/or a doubling of CA-125 levels ≥ 70 IU/mL following first-line chemotherapy
• •Measurable disease as defined by RECIST criteria
• •No CNS metastases
• •PATIENT CHARACTERISTICS:
• •ECOG performance status 0-2
• •Absolute neutrophil count ≥ 1,500/μL
• •Hemoglobin ≥ 9.5 g/dL
• •Platelets \> 100,000/μL
• •Serum creatinine ≤ 1.5 times upper limit of normal (ULN)
• •Total bilirubin ≤ 1.5 times ULN
• •AST and ALT ≤ 2.5 times ULN (≤ 5.0 times ULN if liver metastases are present)
• •LVEF ≥ 50% by MUGA
• •Not pregnant or nursing
• •Negative pregnancy test
• •Surgically sterile or must use effective contraception
• •No known HIV positivity or AIDS
• •No uncontrolled heart disease, diabetes, or other medical condition that would place the patient at unacceptably high risk for toxicity
• •No New York Heart Association class I-IV heart failure